[pubmed] Clinical Utility of Striational Antibodies in Paraneoplastic and Myasthenia Gravis Paraneoplastic Panels
Posté : 27 avr. 2021 12:00
Neurology. 2021 Apr 26:10.1212/WNL.0000000000012050. doi: 10.1212/WNL.0000000000012050. Online ahead of print.
ABSTRACT
OBJECTIVE: To critically assess the clinical utility of striational antibodies (StrAbs) within paraneoplastic and myasthenia gravis serological evaluations.
METHODS: All Mayo Clinic patients tested for StrAbs from January 1st 2012-December 31st 2018 utilizing Mayo's Unified Data Platform (UDP) were reviewed for neurological diagnosis and cancer.
RESULTS: 38,502 unique paraneoplastic and 1,899 MG patients were tested. In paraneoplastic evaluations, the StrAbs positivity rate was higher in cancer vs without cancer (5% [321/6775] vs 4% [1154/31727]; p
Source: https://pubmed.ncbi.nlm.nih.gov/3390319 ... 6&v=2.14.4